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Race and gender representation of hypertrophic  
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African research setting
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Summary
We	 researched	 hypertrophic	 cardiomyopathy	 (HCM)	 and	




We	 trawled	our	database	 entries	 over	 the	past	 20	 years	
to	identify	all	cases	of	heart	muscle	and	arrhythmic	disease.	
Among	 these,	we	 separated	 the	 index	 cases	 from	 the	 rest	









were	 almost	 exclusively	white	Caucasian	 (n	5	 36,	 88%	of	
lQTS	index	cases),	with	four	cases	(9.8%)	of	MA,	one	(2.4%)	
of	 indian/Asian	 and	none	 of	 black	African	descent.	These	
race	demographics	did	not	fit	the	national	demographics	for	
South	Africa	as	a	whole.	in	contrast,	in	both	groups,	gender	
biases	 (slightly	more	male	 than	 female	HCM	cases,	 and	 a	
0.4	 ratio	 of	males	 to	 females	 in	lQTS)	previously	 report-
ed	 elsewhere	 appeared	 to	 be	 replicated	 in	 our	 database.	
Genetic	 bias	 is	 an	 unlikely	 explanation	 for	 the	 skewed	
demographics	 in	 our	 database;	 a	more	 likely	 explanation	
relates	 to	 various	missed	opportunities	 to	diagnose,	missed	
diagnoses	 and	misdiagnoses,	 as	well	 as	 the	 real	population	
drainage	 of	 our	main	 referral	 centre	 in	 the	 context	 of	 a	
differentiated	healthcare	system.	
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Over the last 20 years, scientific endeavours aimed at mapping 
Mendelian inherited disease to chromosomal segments often 
uncovered causal genes of an unanticipated nature. These unpre-
dicted genes pointed to and paved the way for the exploration of 
novel pathological mechanisms leading to morbidity and death, 
the understanding of which, potentially, could also benefit 
sufferers from common disease, as similar pathways may be at 
play in both the common complex and rarer inherited diseases.1 
A now-classic example of the benefits of understanding the 
pathophysiology of inherited disease, which even predates the 
molecular era, is that of studies of familial hypercholesterolae-
mia (FH), an autosomal dominantly inherited disease. These 
studies lead to the identification of the key role that the enzyme 
3-hydroxy-3-methylglutaryl coenzyme A reductase (HMG-
CoA) plays in the control of intracellular cholesterol synthesis 
and the current widespread use of ‘statin’ drugs.2,3 
Our molecular genetic research has, for the last two decades, 
focused on inherited heart disease, primarily hypertrophic 
cardiomyopathy (HCM), the long QT syndrome (LQTS) and 
familial conduction disease. In a family context, these diseases 
are very often asymptomatic, but with the risk of syncope as the 
result of an arrhythmia, or more dire, death, during an arrhyth-
mic event. Analogous to the FH example, we investigated these 
diseases as models for studying the pathophysiology of two 
phenomena, namely, arrhythmias and hypertrophy, which are 
common to a variety of cardiac conditions. In the process, we 
have had the opportunity to compare local disease profiles with 
global patterns. 
In this regard, we find it intriguing that, although the gender 
distribution for HCM and LQTS in our patient database was 
in accordance with international male:female ratios for these 
diseases, the racial distribution was not representative of 
national demographics. We describe the extent of this lack of 
representation and speculate on the likely reasons. The conduc-
tion diseases are excluded, as they have been uniquely described 
in this country, and cannot be meaningfully compared with 
reports elsewhere. 
Methods
Demographic details of patients with cardiac conditions are 
routinely entered into our patient database at their referral for 
genetic investigations by our laboratory. Diagnosis of LQTS4 
and HCM5 were made by criteria previously reported. 
We trawled this database to identify all cases of heart muscle 
and arrhythmic disease. Among these, we separated the index 
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cases from the rest of their family members, segregating for the 
relevant heart disease so that numbers were not biased by family 
size, and analysed the race and gender composition of the HCM 
and LQTS sectors. 
In order to ascertain the frequency of HCM and LQTS 
reported from Africa, a MEDLINE search was performed with 
the search terms ‘hypertrophic cardiomyopathy’ and ‘Africa’. 
The same search was repeated but using all African country 
names individually. A similar search was conducted for the long 
QT syndrome or its eponym, namely, ‘Romano-Ward’ or ‘Ward-
Romano’ syndrome. 
Results and discussion
A total of 743 cases (286 index cases) of various heart, heart 
muscle and conduction diseases were seen or referred and 
entered into the database during the period 1986 to 2006. Of 
these 371 (176 index cases, 62% of index cases) had hyper-
trophic cardiomyopathy and 246 (41 index cases, 14% of index 
cases) had LQTS. 
The majority of HCM index cases (n 5 90, 51.1% of 
HCM index cases) were of mixed ancestry (MA), with white 
Caucasian ancestry following closely behind with 74 cases 
(42.0%). Very few black African (n 5 9, 5.1%) or Indian/Asian 
(n 5 3, 1.7%) cases were seen or referred (Table 1). The LQTS 
index cases were almost exclusively white Caucasian (n 5 36, 
88% of LQTS index cases), with four cases (9.8%) of MA, 
one (2.4%) of Indian/Asian and none of black African descent 
(Table 2). National demographics for South Africa as a whole 
(42 million people) are given as 35.4 million (79%) black 
Africans, 4.2 million (9.6%) white Caucasian, 4 million (8.9%) 
of mixed ancestry and 1.1 million (2.5%) Indian/Asian.6 
Gender breakdown in the HCM index case group was 110 
males (62.5%) versus 66 females (37.5%), whereas in the LQTS 
group, 12 patients (29.3%) were male, compared to 29 (71.7%) 
females. In the HCM group, the male-to-female ratio varied 
from 1.1 in MA, to 2.0 in black and Indian/Asian, and 2.7 in 
white patients (Table 1). In LQTS, a male-to-female ratio of 0.4 
was maintained in the white and MA groups. The ratio could 
not be established for black and Indian/Asian patients due to 
low numbers (Table 2). Therefore, in both groups, gender biases 
(more male than female HCM cases,7,8 and a 0.4 ratio of males 
to females in LQTS) previously reported elsewhere appeared to 
be replicated in our database.9
However, although gender demographics were maintained 
for both diseases, the question remains why very few persons of 
black African descent with HCM and none with LQTS appeared 
in our database. HCM in black individuals has been infrequently 
reported from South Africa10-12 and more recently, in two reports, 
also from other African countries,13,14 although HCM was found 
to be more than twice as prevalent in black Americans as in 
white Americans in a prospective study.7 
For LQTS, where the diagnosis is made on syncope and a 
prolonged QT interval on an ECG, not a single case report from 
Africa can be traced in the literature, despite the long-standing 
and common availability of the diagnostic technology. Those 
reports from Africa on QT variation pertain to conditions other 
than LQTS, such as kidney failure,15 HIV/AIDS,16 eclampsia,17 
Kwashiorkor18 and treatment of malaria with halofantrine.19 Yet, 
the ratio of black American to white American LQTS patients 
was almost 1.5:1, and that of Asian American to white American 
almost 1:1 in a panel of patients referred for genetic screening in 
the USA.20 The paucity of reports of HCM and LQT from Africa 
begs an explanation, and may relate to the genetics or the clini-
cal diagnoses of these inherited cardiac conditions. 
The prevalence of Mendelian inherited disease, imply-
ing causal genetic mutations with strong pathological effects 
could become racially restricted for a variety of reasons, such 
as genetic drift, mutation rates and selection. For example, 
myotonic dystrophy is a disease that is, barring a single report, 
not reported from Africa, but is observed more frequently in 
other areas of the world. An explanation for this phenomenon 
has been based on the absence of a single ancestral mutation-
predisposing genetic state (pre-mutation) of a chromosomal 
segment in African populations, while this same pre-mutation is 
present in populations elsewhere that derived from the African 
diaspora.21,22 This may represent an instance of genetic drift, 
where the pre-mutation simply drifted into non-existence in the 
African populations. An alternative explanation is that the muta-
tion might only have occurred in the migrant population from 
which the rest of the world population then derived. 
This scenario is extremely unlikely for both HCM and 
LQTS, as many de novo mutations have been described for both. 
For hypertrophic cardiomyopathy, more that 400 mutations in 
12 different genes, located on different chromosomal regions, 
have been described,23 and similarly, for LQTS more than 
400 mutations in eight differentially located genes24 exist. The 
disease-causing mutations are most often ‘private’, meaning 
that such genetic defects generally arise independently in each 
given family, even when mutations appear to be shared, and so 
will not be associated with any particular allelic chromosomal 
segment in a population. Also, as would be expected of disease 
alleles, no increase to the level of polymorphic frequencies 
through positive selection or through drift has been reported. 
Therefore, for both diseases, individuals carrying disease-caus-
ing mutations should be present in all population groups to the 




Ancestry Number % of total F M M:F
Black 9 5.1 3 6 2.0
Indian/Asian 3 1.7 1 2 2.0
MA 90 51.1 42 48 1.1
White 74 42.0 20 54 2.7
Total 176 100 66 110 1.7




Ancestry Number % of total F M M:F
Black 0
Indian/Asian 1 2.4 1 − −
MA 4 9.8 2 2 −
White 36 87.8 26 10 0.4
Total 41 100 29 12 0.4
F 5 female, M 5 male, M:F 5 male-to-female ratio, MA 5 mixed 
ancestry.
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One possible explanation revolves around penetrance of the 
diseases, that is, the probability that an individual carrying a 
disease-causing mutation will manifest the disease clinically. 
Both diseases are characterised by variability of presentation, 
even within family members bearing the same mutation, 
supporting the notion of additional modifying environmental 
or genetic factors influencing the final disease picture. If modi-
fiers of either type, which on one hand exacerbate disease 
severity such that early death, an example of selection, removes 
such individuals from the population, or, on the other hand, 
ameliorate disease presentation to asymptomatic longevity, 
are particularly prevalent in some populations, disease demo-
graphics would be skewed. However, the racial demographics 
from overseas studies mentioned earlier suggest that this is an 
unlikely scenario.
We therefore need to question whether other selection biases, 
such as identification bias, may be operating. Certainly, the fact 
that many of our patient base reported to Tygerberg Hospital, 
which primarily drained traditionally white and MA sectors of 
the Cape metropole is a factor. However, our presence in the 
Western Cape at a historically white university is unlikely to be 
the only explanation. Our work has been vigorously propounded 
countrywide, through active exposure at local academic meet-
ings, public talks and the media and direct mass mailing to clini-
cians. We have, for example, in recent years mailed more than 
2 000 letters to physicians and cardiologists across the country, 
explaining our LQTS research and requesting participation. 
Therefore, barring apathy on the part of potentially participating 
clinicians or patients, one might still draw the conclusion that 
the prevalence of manifest HCM and LQT differs among our 
subpopulations. 
Another, and in our opinion, the most likely reason for the 
phenomenon may relate to a recognition bias, and such recogni-
tion biases may have multiple causes, involving both missed 
opportunities to diagnose (because the patient never comes to 
clinical attention), missed diagnoses and misdiagnoses. 
Both HCM and LQTS diagnoses depend on the availability 
of equipment, mainly echocardiography for HCM and ECG 
for LQTS, utilisation of this equipment and the interpretation 
of the tests performed with such equipment. In HCM, where 
patients are often asymptomatic or mildly affected and symp-
tomatic, referral for diagnostic echocardiographic investigation 
often springs from clinical identification of a systolic murmur. 
Echocardiography is less widely available than, for instance, 
ECG, and certainly, in the past the paucity of reporting of 
this disease from Africa has been attributed to unavailability 
of echocardiography.25,26 However, this is no longer likely to 
be the limiting factor in Africa’s big cities. On the other hand, 
echocardiography is more time consuming and dependent on 
specialised skills, and such constraints in the context of other 
overwhelming healthcare priorities in a primary-care setting 
may lead to lower referral rates and consequently missed oppor-
tunities for diagnosis. 
In LQTS on the other hand, ECG availability and interpreta-
tion are not generally problematical; rather, interpretation of 
episodes of transient loss of consciousness (TLOC) may result in 
misdiagnoses. If, for example, an episode of TLOC is regarded 
as epilepsy, ECG is conventionally simply not performed. The 
correct interpretation of TLOC derives from awareness among 
clinicians of the correct questions to ask in order to obtain a 
differentiating case history, and awareness among the public 
about the difference between ‘fits’ and other causes of TLOC.27 
It is very disconcerting that the same graduate students who 
pass or fail examinations on their ability to identify murmurs, 
are never examined on their ability to differentiate TLOC. 
Certainly, the extent of misdiagnoses in LQTS is substantial. 
When we started researching LQTS in 1992, more than 80% 
of diagnosed LQTS patients had at some previous stage been 
diagnosed, and often treated, as epileptics.28
We must accept that in both hypertrophic cardiomyopathy 
and in the long QT syndrome, opportunities to diagnose such 
patients may not present themselves and when they do present, 
the diagnosis may be missed. A likely reason is that in a coun-
try where premature death most often occurs in obviously ill 
persons, most often suffering from infectious disease,29 diseases 
in those more apparently well may simply go undiagnosed, even 
when such diseases convey a high risk of death, such as HCM 
and LQT. A much reported case from the Cameroon, Africa, has 
been that of Marc Vivian Foë, a world-class soccer player, where 
the diagnosis of HCM was made only after he collapsed and 
died on a soccer field in France.30 In the time- and manpower-
pressured setting of primary healthcare clinics in Africa, a less 
sophisticated service and a language barrier during translation 
of questions and answers may lead to loss of diagnostic subtle-
ties, whereas the same constraints may not apply to private 
healthcare settings. Therefore the bias in our database may be a 
combined reflection of the real population drainage of our main 
referral centre (Tygerberg Hospital) and the consequence of a 
differentiated healthcare system nationwide. 
Conclusions
The most plausible reasons for demographic differences in the 
prevalence of HCM and LQTS in the South African population 
as reflected in our database probably relate to various missed 
opportunities to diagnose, missed diagnoses and misdiagnoses 
in the context of a differentiated healthcare system. With a high 
emphasis on persons with obvious physical disease, diseases 
that often manifest as less chronic and less severe are simply 
not diagnosed. Yet, the medical and lay community should be 
made aware of such diseases as young lives could be saved by 
the timely institution of appropriate therapy.
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We regret a typographical error in Cardiovasc J Afr 2007; 
18(4): 262 and apologise to our readership and the author Dr 
Straughan. Below is the correction for the article How well do 
we know the opioids for providing good analgesia? by Dr John 
L Straughan.
The authoritative American Hospital Formulary Service 
(AHFS − 2007; 49th edn)10 recommends for patients older than 
12 years, that intravenous doses of 3	to	4	mg (not 3 to 4 mg/
kg) may need to be repeated as often as every five minutes to 
achieve adequate pain relief in acute situations.
Patients with unstable angina, who do not respond adequately 
to appropriate nitroglycerin administration, may require intrave-
nous morphine at a dosage of 2	 to	 5	mg (not 2 to 5 mg/kg) 
every five to 30 minutes to relieve pain and allay anxiety. Small 
incremental doses are preferred to larger and less-frequent doses 
in order to minimise the risks of adverse repercussions, and to 
allow better titration to optimal pain relief.
Erratum
